LMO3 and central nervous system cancer: MiR-101 inhibits the expression of EZH2 and DNMT3A, which leads to increased levels of H3K4me3 and H4K20me3 in the core promoter region of LIM domain only 3 (LMO3), thereby inhibiting the expression of LMO3 and metastasis of glioma cells [60].